gms | German Medical Science

Frühjahrstagung der Sektion Antimykotische Chemotherapie 2017

Paul-Ehrlich-Gesellschaft für Chemotherapie (PEG e. V.)

17. - 18.03.2017, Bonn

Diagnostic Performance of 1,3-Beta-D-Glucan Serum Screening in Patients after Liver Transplantation

Meeting Abstract

  • corresponding author J. Dziobaka - Universitätsklinikum Essen, Institut für Medizinische Mikrobiologie, Essen
  • J. Rekowski - Universitätsklinikum Essen, Institut für Medizinische Informatik, Biometrie und Epidemiologie, Essen
  • F. Saner - Universitätsklinikum Essen, Klinik für Allgemein-, Viszeral- und Transplantationschirurgie, Essen
  • J. Buer - Universitätsklinikum Essen, Institut für Medizinische Mikrobiologie, Essen
  • P.-M. Rath - Universitätsklinikum Essen, Institut für Medizinische Mikrobiologie, Essen
  • J. Steinmann - Universitätsklinikum Essen, Institut für Medizinische Mikrobiologie, Essen

Paul-Ehrlich-Gesellschaft für Chemotherapie e.V. (PEG). Frühjahrstagung der Sektion Antimykotische Chemotherapie 2017. Bonn, 17.-18.03.2017. Düsseldorf: German Medical Science GMS Publishing House; 2017. Doc17sac12

doi: 10.3205/17sac12, urn:nbn:de:0183-17sac127

Veröffentlicht: 13. März 2017

© 2017 Dziobaka et al.
Dieser Artikel ist ein Open-Access-Artikel und steht unter den Lizenzbedingungen der Creative Commons Attribution 4.0 License (Namensnennung). Lizenz-Angaben siehe http://creativecommons.org/licenses/by/4.0/.


Gliederung

Text

Introduction: Liver transplant recipients are at higher risk for developing an invasive fungal infection (IFI). 1,3-beta-d-glucan (BDG) is a fungal serum biomarker that can be used in the diagnosis of IFI. In this study, we evaluated the diagnostic performance of BDG screening in patients receiving a cadaveric liver transplantation.

Methods: Patients who received a cadaveric liver transplant between June 2013 and May 2015 were retrospectively enrolled in this single center study. BDG levels in serum samples were determined by using the Fungitell® assay. BDG levels ≥80 pg/ml were considered as positive. According to the revised EORTC/MSG criteria for IFI, patients’ diseases were classified as proven, probable or no evidence of IFI.

Results: A total of 509 serum samples were obtained from 104 patients during their first inpatient period post transplantation. No patient received antifungal prophylaxis. 11 patients fulfilled criteria for proven or probable IFI. For weeks 1 to 4 after transplantation sensitivity, specificity, Youden index (YI), positive predictive value, negative predictive value and diagnostic odds ratio for a minimum cut off-value of 221 pg/ml (maximum YI) amount 0.55, 0.91, 0.45, 0.43, 0.94 and 12.8, respectively.

Conclusion: BDG screening may be helpful in ruling out IFI in liver transplant recipients.